LENZ Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 LENZ Therapeutics Inc 公司

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Inc簡介



公司代碼LENZ

公司名稱LENZ Therapeutics Inc

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

員工數量42

證券類型Ordinary Share

年結日Jun 25

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

國家- -

郵編- -

電話- -

網址- -

公司代碼LENZ

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

LENZ Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. James Mccollum

Independent Director

631.10K

--

Mr. Marc Odrich

Chief Medical Officer

100.20K

+0.60%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

12.89K

+58.20%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

--

Jeff W. George

Independent Chairman of the Board

--

Ms. Shelley B. Thunen

Independent Director

--

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. James Mccollum

Independent Director

631.10K

--

Mr. Marc Odrich

Chief Medical Officer

100.20K

+0.60%

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

12.89K

+58.20%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

--

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

--

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

--

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 5月13日週三

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

13.33%

Fidelity Management & Research Company LLC

11.81%

Alpha Wave Global, LP

11.52%

Versant Ventures

8.47%

Squarepoint Capital LLP

5.08%

其他

49.79%

持股股東

佔比

RA Capital Management, LP

13.33%

Fidelity Management & Research Company LLC

11.81%

Alpha Wave Global, LP

11.52%

Versant Ventures

8.47%

Squarepoint Capital LLP

5.08%

其他

49.79%

股東類型

持股股東

佔比

Investment Advisor

42.54%

Venture Capital

33.60%

Investment Advisor/Hedge Fund

21.57%

Hedge Fund

14.43%

Individual Investor

2.65%

Research Firm

2.10%

Pension Fund

0.54%

Bank and Trust

0.16%

Private Equity

0.16%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

347

36.30M

115.82%

+853.08K

2025Q4

309

33.95M

108.49%

+1.00M

2025Q3

267

30.95M

100.67%

+981.38K

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

4.18M

13.33%

--

Dec 31, 2025

Fidelity Management & Research Company LLC

3.70M

11.81%

+3.62M

+4140.74%

Dec 31, 2025

Alpha Wave Global, LP

3.61M

11.52%

--

Dec 31, 2025

Versant Ventures

2.66M

8.47%

--

Dec 31, 2025

Squarepoint Capital LLP

491.90K

1.57%

+402.11K

+447.84%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

1.47M

4.68%

+146.33K

+11.08%

Dec 31, 2025

abrdn Inc.

489.43K

1.56%

+358.71K

+274.40%

Dec 31, 2025

Franklin Advisers, Inc.

1.09M

3.48%

+540.65K

+98.41%

Dec 31, 2025

72 Investment Holdings, LLC

1.02M

3.25%

--

Dec 31, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.27%

iShares U.S. Pharmaceuticals ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.11%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares Biotechnology ETF

0.06%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.27%

iShares U.S. Pharmaceuticals ETF

佔比0.22%

ProShares Ultra Nasdaq Biotechnology

佔比0.11%

iShares Micro-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.08%

iShares Biotechnology ETF

佔比0.06%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

公告日期

除權除息日

類型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1